ArriVent BioPharma (AVBP) Competitors $17.42 -0.57 (-3.16%) Closing price 08/11/2025 03:59 PM EasternExtended Trading$17.40 -0.02 (-0.12%) As of 08/11/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. ALVO, GMTX, MIRM, AMRX, NAMS, KNSA, OGN, ARWR, CNTA, and RXRXShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Alvotech (ALVO), Gemini Therapeutics (GMTX), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Arrowhead Pharmaceuticals (ARWR), Centessa Pharmaceuticals (CNTA), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Its Competitors Alvotech Gemini Therapeutics Mirum Pharmaceuticals Amneal Pharmaceuticals NewAmsterdam Pharma Kiniksa Pharmaceuticals International Organon & Co. Arrowhead Pharmaceuticals Centessa Pharmaceuticals Recursion Pharmaceuticals Alvotech (NASDAQ:ALVO) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership. Does the media prefer ALVO or AVBP? In the previous week, Alvotech and Alvotech both had 7 articles in the media. Alvotech's average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ALVO or AVBP more profitable? Alvotech has a net margin of 16.42% compared to ArriVent BioPharma's net margin of 0.00%. Alvotech's return on equity of -36.37% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech16.42% -36.37% 12.70% ArriVent BioPharma N/A -49.21%-46.61% Which has better valuation and earnings, ALVO or AVBP? ArriVent BioPharma has lower revenue, but higher earnings than Alvotech. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$491.98M5.22-$231.86M$0.3723.03ArriVent BioPharmaN/AN/A-$80.49M-$3.77-4.62 Which has more risk and volatility, ALVO or AVBP? Alvotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Do analysts prefer ALVO or AVBP? Alvotech currently has a consensus target price of $14.00, indicating a potential upside of 64.32%. ArriVent BioPharma has a consensus target price of $39.29, indicating a potential upside of 125.51%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders and institutionals have more ownership in ALVO or AVBP? 9.5% of ArriVent BioPharma shares are owned by institutional investors. 18.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryArriVent BioPharma beats Alvotech on 8 of the 14 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$615.48M$3.00B$5.48B$9.72BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-4.6217.0529.7724.63Price / SalesN/A347.15453.22102.60Price / CashN/A40.7324.8127.99Price / Book2.288.898.595.76Net Income-$80.49M-$54.75M$3.26B$264.95M7 Day Performance-10.43%-2.71%-0.32%-0.01%1 Month Performance-19.46%4.43%2.14%1.27%1 Year Performance-22.23%19.64%44.52%26.11% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma1.6395 of 5 stars$17.42-3.2%$39.29+125.5%-19.8%$615.48MN/A-4.6240News CoverageEarnings ReportUpcoming EarningsHigh Trading VolumeALVOAlvotech3.3893 of 5 stars$8.71-1.8%$14.00+60.7%-21.9%$2.63B$491.98M23.541,032Upcoming EarningsGMTXGemini TherapeuticsN/A$59.79+1.4%N/A+34.7%$2.59BN/A-59.7930MIRMMirum Pharmaceuticals4.0394 of 5 stars$52.06-0.4%$65.50+25.8%+64.6%$2.58B$336.89M-32.33140Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionAMRXAmneal Pharmaceuticals3.3469 of 5 stars$8.14+2.2%$11.60+42.5%+15.6%$2.55B$2.79B-203.328,100Earnings ReportNAMSNewAmsterdam Pharma3.5786 of 5 stars$21.80+0.6%$41.30+89.5%+40.1%$2.45B$47.14M-11.594Trending NewsEarnings ReportAnalyst RevisionKNSAKiniksa Pharmaceuticals International3.2037 of 5 stars$33.02+0.2%$41.17+24.7%+30.1%$2.41B$423.24M825.43220OGNOrganon & Co.4.7493 of 5 stars$8.74-9.7%$18.00+106.1%-55.3%$2.30B$6.40B3.074,000Earnings ReportDividend AnnouncementARWRArrowhead Pharmaceuticals3.6807 of 5 stars$16.470.0%$43.71+165.5%-26.5%$2.28B$545.21M-11.79400Earnings ReportAnalyst ForecastCNTACentessa Pharmaceuticals3.109 of 5 stars$16.78+4.3%$28.10+67.5%+50.5%$2.24B$6.85M-9.27200RXRXRecursion Pharmaceuticals2.2709 of 5 stars$5.47-5.7%$7.00+28.0%-15.9%$2.23B$58.84M-3.09400Earnings Report Related Companies and Tools Related Companies Alvotech Competitors Gemini Therapeutics Competitors Mirum Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Kiniksa Pharmaceuticals International Competitors Organon & Co. Competitors Arrowhead Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access